Skip to main content

Table 3 Medications and doses of all 21 subjects enrolled in the study

From: Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cells

Patient Medication group Medication name Dose/unit Freq
1 INSTI Descovy + Isentress 600 (2)-200-25 QD
2 INSTI Truvada and Tivicay 200 QD
3 INSTI Triumeq 600-50-300 QD
4 INSTI Triumeq 600-50-300 QD
5 INSTI Genvoya 150-150-200 QD
6 INSTI Biktarvy 50-200-25 QD
7 INSTI Tivicay and Descovy 50-200-25 QD
8     
9 INSTI Juluca 50-25 QD
10 NNRTI Odefsey (Rilpivirine) 200-25-25 QD
11 INSTI Juluca 50-25 QD
12 INSTI Genvoya 150-150-200 QD
13 NNRTI Odefsey 200-25-25 QD
14 NNRTI Atripla (Efivarenz) 600-200-300 QD
15   Patient dropped out   
16 NNRTI Odefsey 200-25-25 QD
17 INSTI Biktarvy 50-200-25 QD
18 NNRTI Odefsey 200-25-25 QD
19 NNRTI Epzicom + Viramune 600-300 QD
20     
21 INSTI Descovy + Isentress 200-25 QD
22 INSTI Descovy + Tivacay 200-25 QD